{"analyses":[{"ciLowerLimit":"1.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.27","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.012","paramType":"Odds Ratio (OR)","paramValue":"4.63","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"4.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"43.93","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"14.42","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"8.8","value":"3.1"},{"groupId":"OG001","lowerLimit":"8.4","upperLimit":"21.1","value":"13.5"},{"groupId":"OG002","lowerLimit":"26.8","upperLimit":"41.0","value":"33.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"167"}],"units":"Participants"}],"description":"ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets administered orally QD.","id":"OG000","title":"Placebo Phase 3"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib Phase 3"},{"description":"Participants received one 4 mg Baricitinib tablet administered orally QD, and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib Phase 3"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 participants with baseline ClinRO measure for EL hair loss ≥ 2 and who had evaluable data for this outcome measure. A Non-responder Imputation (NRI) was applied for participants with missing data at the timepoint due to discontinuation or other intercurrent events.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3","type":"SECONDARY","unitOfMeasure":"percentage of participants"}